Retraction
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
Paper Information
Retraction Details
Citations (5)
5
Total Citations0
Post-Retraction4
Pre-Retraction0
Same DayHeavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Andrei Havași, Simona Căinap, Ana Teodora Havasi et al. (4 authors)
Medicina
Open Access
Published: Mar 2023
61 citations
61 citations
110 days before retraction
Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
Xiu Chen, Qinglian Wen, Liqiu Kou et al. (6 authors)
BMC Cancer
Open Access
Published: Jan 2023
7 citations
7 citations
148 days before retraction
Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum‐Resistant Recurrent Ovarian Epithelial Carcinoma
Computational and Mathematical Methods in Medicine
Computational and Mathematical Methods in Medicine
Open Access
Published: Jan 2023
178 days before retraction
Effect of bevacizumab plus paclitaxel and carboplatin regimen on prognostic survival of ovarian cancer patients.
Qingling Jiang, Hong Qian, Lin Mei et al. (9 authors)
PubMed
Published: Jan 2022
1 citation
1 citation
543 days before retraction
Quick Stats
Total Citations:
7
Years Since Retraction:
2.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025